ArticleScientific reports2022
Compositions of gut microbiota before and shortly after hepatitis C viral eradication by direct antiviral agents.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Gut Microbiota Recovery After Direct-Acting Antiviral Therapy for Chronic Hepatitis C: A Systematic Review and Meta-Analysis.Microorganisms · 2026Review
- Association of small intestinal bacterial overgrowth with portal hypertension in HCV-related cirrhosis: a cross-sectional study.Clinical and experimental medicine · 2026Article
- Gut microbiome-based strategies for HIV prevention and therapy, current challenges and future prospects.Gut pathogens · 2026Review
- Interplay between viral infections and gut microbiota dysbiosis: Mechanisms and therapeutic potential.World journal of gastroenterology · 2026Review
- Metagenomic profiling of gut microbiome signatures across liver disease stages and HCV-related hepatocellular carcinoma in Egyptian patients.Frontiers in microbiology · 2026Article
- Gut Microbiota and the Gut-Liver Axis in Liver Disease: From Chronic Viral Hepatitis to Cirrhosis, Hepatocellular Carcinoma, and Microbiome-Based Therapies.Microorganisms · 2025Review
- The effects of restraint stress and orthodontic tooth movements on the intestinal epithelial structure and metabolic function in rats.PloS one · 2025Article
- Gut microbiota in liver diseases: initiation, development and therapy.Frontiers in medicine · 2025Review
- Direct-acting antiviral treatment significantly shaped the gut microbiota in chronic hepatitis C patients: a pilot study.Frontiers in microbiology · 2025Article
- Insights of gut-liver axis in hepatic diseases: Mechanisms, clinical implications, and therapeutic potentials.World journal of gastrointestinal pharmacology and therapeutics · 2024Review
- Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions.World journal of hepatology · 2024Review
- Association of homelessness and diet on the gut microbiome: a United States-Veteran Microbiome Project (US-VMP) study.mSystems · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is unclear whether dysbiosis in hepatitis C virus (HCV) infected patients results from the viral infection per se or develops as a result of hepatic dysfunction. We aimed to characterize compositions in gut microbiome before and shortly after HCV clearance. In this prospective cohort study, adult patients with confirmed HCV viremia were screened before receiving direct antiviral agents. Those with recent exposure to antibiotics or probiotics (within one month), prior abdominal surgery, or any malignancy were ineligible. Stool was collected before antiviral therapy started and at 12 weeks after the treatment completed. From the extracted bacterial DNA, 16 s rRNA gene was amplified and sequenced. Each patient was matched 1:2 in age and sex with uninfected controls. A total of 126 individuals were enrolled into analysis. The gut microbiome was significantly different between HCV-infected patients (n = 42), with or without cirrhosis, and their age-and sex-matched controls (n = 84) from the levels of phylum to amplicon sequence variant (all p values < 0.01 by principal coordinates analysis). All patients achieved viral eradication and exhibited no significant changes in the overall composition of gut microbiome following viral eradication (all p values > 0.5), also without significant difference in alpha diversity (all p values > 0.5). For the purpose of exploration, we also reported bacteria found differently abundant before and after HCV eradication, including Coriobacteriaceae, Peptostreptococcaceae, Staphylococcaceae, Morganellaceae, Pasteurellaceae, Succinivibrionaceae, and Moraxellaceae. Gut microbiota is altered in HCV-infected patients as compared with uninfected controls, but the overall microbial compositions do not significantly change shortly after HCV eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.